Investor Relations

Latest Financial Results

Q1 2021

Quarter Ended Mar 31, 2021
Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2020

Company Overview

NRx is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. NRx recently announced a commercial partnership with Relief Therapeutics Holding AG for global commercialization of ZYESAMI™️️ (Aviptadil), an application for COVID-related respiratory failure (the "NRx COVID-19 Drug"). NRx is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior (the "NRx Antidepressant Drug Regimen"). NRx Pharmaceuticals (Nasdaq: NRXP), formerly NeuroRx, is now traded on the Nasdaq Global Select Exchange.

IR Contacts

Company

NRx Pharmaceuticals, Inc.
1201 Orange St.
Ste 600
Wilmington, DE 19801
T: 484-254-6134

Investor Relations

Ryan Sheffield
Chief of Staff
T: 484-254-6134 ext. 723
rsheffield@nrxpharma.com

Transfer Agent

Continental Stock Transfer & Trust